Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer.

Date publication

février 2025

Journal

Journal for immunotherapy of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier , Pr GHIRINGHELLI François

Tous les auteurs :
Talpin A, Maia A, Carpier JM, Kulakowski G, Aubergeon L, Kervevan J, Gaal C, Strozzi F, Billerey C, Amable L, Mersceman T, Garnier A, Oliveira C, Calderon C, Bachrouche D, Ventujol C, Bernard L, Manteau A, Martinez J, Bonnet M, Noguerol J, Laviolette K, Boullerot L, Malfroy M, Chevalier G, Adotevi O, Joffre O, Idbaih A, Vieito M, Ghiringhelli F, Stradella A, Tabatabai G, Burger MC, Mildenberger I, Herrlinger U, Reardon DA, Wick W, Gouttefangeas C, Bonny C, Chene L, Gamelas Magalhaes J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39979071

Résumé

Molecular mimicry between commensal bacterial antigens and tumor-associated antigens (TAAs) has shown potential in enhancing antitumor immune responses. This study leveraged this concept using commensal bacterial antigens, termed OncoMimics, to induce TAA-derived peptide (TAAp)-specific cross-reactive cytotoxic T cells and improve the efficacy of peptide-based immunotherapies.

Mots clés

Adaptive, Human leukocyte antigen - HLA, Immunotherapy, T cell, Vaccine

Référence

J Immunother Cancer. 2025 02 20;13(2):